Department Cell Biology, Albert Einstein College Medicine, New York, NY 10461, USA.
Cell. 2014 Feb 13;156(4):625-6. doi: 10.1016/j.cell.2014.01.059.
Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.
抗血管内皮生长因子 (VEGF) 癌症免疫疗法以血管生成作为靶点,但患者的耐药性发展较为常见。在本期《Cell》中,Croci 等人确定了一系列复杂的机制,通过这些机制,半乳糖凝集素-1 延长了血管内皮生长因子受体 2 (VEGFR2) 的细胞表面保留时间,并刺激了 VEGF 非依赖性肿瘤血管生成。